NHMRC Centre for Research Excellence in Frailty and Healthy Ageing, Adelaide, South Australia, Australia; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; Institute of Biomedicine, University of Turku, Turku, Finland.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
J Clin Lipidol. 2018 May-Jun;12(3):652-661. doi: 10.1016/j.jacl.2018.02.012. Epub 2018 Mar 2.
Compared to randomized controlled trials, nonexperimental studies often report larger survival benefits but higher rates of adverse events for statin use vs nonuse.
We compared characteristics of statin users and nonusers living in aged care services and evaluated the relationships between statin use and all-cause mortality, all-cause and fall-related hospitalizations, and number of falls during a 12-month follow-up.
A prospective cohort study of 383 residents aged ≥65 years was conducted in six Australian aged care services. Data were obtained from electronic medical records and medication charts and through a series of validated assessments.
The greatest differences between statin users and nonusers were observed in activities of daily living, frailty, and medication use (absolute standardized difference >0.40), with users being less dependent and less frail but using a higher number of medications. Statin use was associated with a decreased risk of all-cause mortality (adjusted hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.37-0.93) and hospitalizations (HR 0.67, 95% CI 0.46-0.98). After exclusion of residents unable to sit or stand, statin use was associated with a nonsignificant increase in the risk of fall-related hospitalizations (HR 1.47, 95% CI 0.80-2.68) but with a lower incidence of falls (incidence rate ratio 0.67, 95% CI 0.47-0.96).
The observed associations between statin use and the outcomes may be largely explained by selective prescribing and deprescribing of statins and variation in likelihood of hospitalization based on consideration of each resident's clinical and frailty status. Randomized deprescribing trials are needed to guide statin prescribing in this setting.
与随机对照试验相比,非实验研究常报告他汀类药物使用与不使用者的生存获益更大,但不良事件发生率更高。
我们比较了居住在老年护理服务中的他汀类药物使用者和不使用者的特征,并评估了他汀类药物使用与全因死亡率、全因和与跌倒相关的住院率以及 12 个月随访期间跌倒次数之间的关系。
对澳大利亚 6 家老年护理服务中的 383 名年龄≥65 岁的居民进行了前瞻性队列研究。数据来自电子病历和药物图表以及一系列经过验证的评估。
他汀类药物使用者和不使用者之间最大的差异出现在日常生活活动、虚弱和用药方面(绝对标准化差异>0.40),使用者依赖性更低、身体更健康,但使用的药物更多。他汀类药物使用与全因死亡率降低相关(调整后的危险比[HR]0.58,95%置信区间[CI]0.37-0.93)和住院风险降低相关(HR0.67,95%CI0.46-0.98)。排除无法坐或站立的居民后,他汀类药物使用与与跌倒相关的住院风险增加无关(HR1.47,95%CI0.80-2.68),但跌倒发生率降低(发病率比[IRR]0.67,95%CI0.47-0.96)。
观察到的他汀类药物使用与结局之间的关联可能主要归因于他汀类药物的选择性处方和停药,以及基于每位居民的临床和虚弱状况考虑住院可能性的变化。需要进行随机停药试验来指导该环境中的他汀类药物处方。